RECORDATI RARE DISEASES PARTNERS WITH THE NATIONAL UREA CYCLE DISORDERS FOUNDATION TO INCREASE AWARENESS OF THE RISKS OF HYPERAMMONEMIA 11/29/2017 European Press Release From Recordati SpA: RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS 06/19/2017 RECORDATI RARE DISEASES INC. ACQUIRES NORTH AMERICAN MARKETING RIGHTS TO CYSTADANE® (BETAINE ANHYDROUS FOR ORAL SOLUTION) 04/13/2017 Pagination First page « First Previous page ‹ Previous … Page 12 Page 13 Current page 14 Page 15 Next page Next › Last page Last »
RECORDATI RARE DISEASES PARTNERS WITH THE NATIONAL UREA CYCLE DISORDERS FOUNDATION TO INCREASE AWARENESS OF THE RISKS OF HYPERAMMONEMIA 11/29/2017
European Press Release From Recordati SpA: RECORDATI LICENSES AN INNOVATIVE TREATMENT FOR NEUROTROPHIC KERATITIS 06/19/2017
RECORDATI RARE DISEASES INC. ACQUIRES NORTH AMERICAN MARKETING RIGHTS TO CYSTADANE® (BETAINE ANHYDROUS FOR ORAL SOLUTION) 04/13/2017
